Chapter 24 Transplant - complications

24.1 CMV disease

VICTOR (2007): - IV ganciclovir vs. oral valganciclovir for non-severe CMV disease. Oral therapy was non-inferior.

IMPACT (2010): - 100 vs. 200 days of valganciclovir prophylaxis in D+R- transplants. Fewer cases of CMV disease by 2 years in the 200-day group.

24.2 CVS risk

ALERT (2003): - fluvastatin vs. placebo in KTRs. Statin therapy for 5 yrs did not significantly reduce the primary end-point (MACE) but did reduce cardiac death and non-fatal MI.